DSpace Repository

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents

Show simple item record

dc.contributor.author Finkelsztejn, A.
dc.contributor.author Gabbai, A.A.
dc.contributor.author Fragoso, Y.D.
dc.contributor.author Carrá, A.
dc.contributor.author Macías-Islas, M.A.
dc.contributor.author Arcega-Revilla, R.
dc.contributor.author García-Bonitto, J.
dc.contributor.author Oehninger-Gatti, C.L.
dc.contributor.author Orozco-Escobar, G.
dc.contributor.author Tarulla, A.
dc.contributor.author Vergara, F.
dc.contributor.author Vizcarra-Escobar, Darwin
dc.date.accessioned 2022-01-18T19:34:40Z
dc.date.available 2022-01-18T19:34:40Z
dc.date.issued 2012
dc.identifier.uri https://hdl.handle.net/20.500.12866/11124
dc.description.abstract Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and NorthAmerican algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. Methods: The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed. Results: A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also discussed. Conclusions: The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to our region directly from purely European and North-American guidelines for treatment. en_US
dc.description.abstract OBJETIVO: Estima que haja aproximadamente 50.000 pessoas com a forma remitente-recorrente da esclerose múltipla na América Latina. Os algoritmos de tratamento norte-americanos e europeus não levam em consideração nossas peculiaridades regionais, nem a dificuldade no acesso ao tratamento por parte dos pacientes. MÉTODOS: O Fórum Latino-americano de Esclerose Múltipla é um grupo de especialistas independente e suprainstitucional, que avaliou as mais recentes evidências científicas sobre a eficácia e a segurança das drogas modificadoras do curso da doença. Foram avaliados também o acesso ao tratamento e os programas de farmacovigilância de cada um dos oito países representados no Fórum. RESULTADOS: Uma lista específica de recomendações baseadas em evidências científicas foi estabelecida para a América Latina. Também foram discutidas perspectivas de futuros tratamentos para esclerose múltipla. CONCLUSÕES: O presente estudo representou um esforço dos representantes de oito países latino-americanos em discutir um assunto que não pode ser adaptado para uso em nossa região diretamente a partir de recomendações de tratamento europeias ou norte-americanas. pt_BR
dc.language.iso eng
dc.publisher SP Academia Brasileira de Neurologia
dc.relation.ispartofseries Arquivos de Neuro-Psiquiatria
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Brazil en_US
dc.subject Latin America en_US
dc.subject South and Central America en_US
dc.subject azathioprine en_US
dc.subject cyclophosphamide en_US
dc.subject drug efficacy en_US
dc.subject drug megadose en_US
dc.subject hematologic disease en_US
dc.subject infection en_US
dc.subject low drug dose en_US
dc.subject methotrexate en_US
dc.subject randomized controlled trial (topic) en_US
dc.subject rituximab en_US
dc.subject disease course en_US
dc.subject treatment outcome en_US
dc.subject sepsis en_US
dc.subject virus detection en_US
dc.subject algorithm en_US
dc.subject drug safety en_US
dc.subject pregnancy en_US
dc.subject alemtuzumab en_US
dc.subject alopecia en_US
dc.subject amenorrhea en_US
dc.subject Argentina en_US
dc.subject atrioventricular block en_US
dc.subject beta interferon en_US
dc.subject blood cell count en_US
dc.subject bradycardia en_US
dc.subject brain atrophy en_US
dc.subject cardiotoxicity en_US
dc.subject clinical trial (topic) en_US
dc.subject cystitis en_US
dc.subject drug approval en_US
dc.subject drug surveillance program en_US
dc.subject Expanded Disability Status Scale en_US
dc.subject fingolimod en_US
dc.subject gadolinium en_US
dc.subject glatiramer en_US
dc.subject hyperthyroidism en_US
dc.subject hypothyroidism en_US
dc.subject leukemia en_US
dc.subject medical decision making en_US
dc.subject methylprednisolone en_US
dc.subject mitoxantrone en_US
dc.subject Multiple sclerosis en_US
dc.subject natalizumab en_US
dc.subject neurologist en_US
dc.subject nuclear magnetic resonance en_US
dc.subject phase 3 clinical trial (topic) en_US
dc.subject progressive multifocal leukoencephalopathy en_US
dc.subject retina macula edema en_US
dc.subject rheumatoid arthritis en_US
dc.subject systematic review (topic) en_US
dc.subject thrombocytopenic purpura en_US
dc.subject thyroiditis en_US
dc.subject Treatment en_US
dc.subject unspecified side effect en_US
dc.subject esclerose múltipla pt_BR
dc.subject tratamento pt_BR
dc.subject América Latina pt_BR
dc.title Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents en_US
dc.title.alternative Algoritmo latino-americano para tratamento da esclerose múltipla remitente-recorrente utilizando drogas modificadoras da doença es_PE
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1590/S0004-282X2012001000009
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.04
dc.relation.issn 1678-4227


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics